Table 3 Patients’ statistics (with survival comparison), each patient as single individual
From: Clinical versus histological grading in the assessment of cutaneous graft versus host disease
Patient statistics (with survival comparison) | ||||
|---|---|---|---|---|
Feature | Grouping/specifics | Frequency | % | p value |
Number of patients | N | 110 | 100.0% | |
Survival patients overall (years) | Mean | 2.96 (SD 2.47) | ||
Gender | Male | 72 | 65.5% | 0.526 |
Female | 38 | 34.5% | ||
Age | Mean | 45.9 (SD 17.5) | ||
0–10 | 8 | 7.3% | 0.328 | |
10–20 | 4 | 3.6% | ||
20–30 | 8 | 7.3% | ||
30–40 | 11 | 10.0% | ||
40–50 | 19 | 17.3% | ||
50–60 | 36 | 32.7% | ||
60–70 | 24 | 21.8% | ||
Disease | Lymphoma | 18 | 16.4% | 0.3137 |
Plasma cell disorders | 23 | 20.9% | ||
MDS/MPN | 12 | 10.9% | ||
Bone marrow failure | 3 | 2.7% | ||
Inherited disorders | 6 | 5.5% | ||
Metabolic disorders | 1 | 0.9% | ||
AML | 25 | 22.7% | ||
CML | 3 | 2.7% | ||
ALL | 11 | 10.0% | ||
CLL | 8 | 7.3% | ||
Donor type | Sibling (SIB) | 34 | 30.9% | 0.1867 |
Cord blood (CB) | 11 | 10.0% | ||
Matched unrelated donor (MUD) | 63 | 57.3% | ||
Other | 2 | 1.8% | ||
Conditioning type | Myeloablative | 17 | 15.5% | 0.2449 |
Non-myeloablative | 72 | 65.5% | ||
Reduced intensity | 21 | 19.1% | ||
Infection after treatment | Overall | 95 | 86.4% | 0.1582 |
CMV | 32 | 29.1% | 0.9485 | |
HHV6 | 10 | 9.1% | 0.2073 | |
EBV | 7 | 6.4% | 0.6031 | |
Aspergillus | 11 | 10.0% | 0.2082 | |
Candida | 31 | 28.2% | 0.2318 | |
Clinical GvHD | Overall (fully documented) including acute GvHD only (a), both acute and chronic GvHD (b) and chronic GvHD (c) | 108 | 98.2% | 0.0037 |
Acute GvHD only (a) | 18 | 16.4% | ||
Both acute and chronic GvHD (b) | 77 | 70.0% | ||
Chronic GvHD only (c) | 13 | 11.8% | ||
Clinical acute GvHD (a+b) | Mean survival (years) | 3.0 (SD 2.6) | ||
Overall no. of patients with documented acute GvHD (a+b) | 95 | 86.4% | ||
aGvHD presentation at date skin biopsy (with no. of biopsies) | 67 (68) | 60.9% | 0.0036 | |
Max. clinical documented aGvHD skin grade reached | 66 | < 0.0001 | ||
Clinical chronic GvHD (b+c) | Mean survival (years) | 3.3 (SD 2.5) | ||
Overall no. of patients with documented chronic GvHD (b+c) | 90 | 81.8% | ||
cGvHD presentation at date biopsy (with no. of biopsies) | 48 (52) | 43.6% | 0.44 | |
Progressive | 13 (15) | |||
Quiescent | 6 (7) | |||
Late onset aGvHD | 19 (20) | |||
De Novo | 4 (4) | |||
Late onset aGvHD after DLI | 6 (6) | |||
Max. clinical documented cGvHD grade reached (including all tracts) | 48 | 43.6% | 0.8844 | |
Max. clinical documented % skin involvement | 46 | 41.8% | 0.7622 | |
0% | 6 | |||
0–25% | 15 | |||
25–50% | 25 | |||
> 50% | 0 | |||